TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model

Ismail M. Meraz; Mourad Majidi; RuPing Shao; Feng Meng; Min Jin Ha; Elizabeth Shpall; Jack A. Roth

doi:10.1038/s42003-022-03103-7

Communications Biology (Feb 2022)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model

Ismail M. Meraz,
Mourad Majidi,
RuPing Shao,
Feng Meng,
Min Jin Ha,
Elizabeth Shpall,
Jack A. Roth

Affiliations

Ismail M. Meraz: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
Mourad Majidi: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
RuPing Shao: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
Feng Meng: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
Min Jin Ha: Department of Biostatistics, Graduate School of Public Health, Yonsei University
Elizabeth Shpall: Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center
Jack A. Roth: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center

DOI: https://doi.org/10.1038/s42003-022-03103-7
Journal volume & issue: Vol. 5, no. 1
pp. 1 – 13

Abstract

Read online

Meraz et al. explore the antitumor efficacy of TUSC2 tumor suppressor genetherapy via nanovisicles in combination with carboplatin and pembrolizumab against KRAS-LKB1 mutant NSCLC in humanized mouse model. They demonstrate a robust response and perform immune profiling studies, which show the development of a cytotoxic T cell effector response and effector memory cells.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal